Browsing by Author "Skarlos, Dimosthenis V."
Now showing items 21-40 of 71
-
Article
Epithelial ovarian cancer in Greece: A retrospective study of 1,791 patients by the hellenic cooperative oncology group (HeCOG)
Pectasides, Dimitrios; Papaxoinis, G.; Fountzilas, George; Aravantinos, Gerasimos; Bamias, A. T.; Pavlidis, Nicholas; Kalofonos, H. P.; Timotheadou, E.; Samantas, E.; Briassoulis, E. Ch; Skarlos, Dimosthenis V.; Economopoulos, T.; Dimopoulos, M. A. (2009)Background: The aim of this retrospective study was to present the epidemiological, pathological and clinical characteristics and treatment results of Greek women with epithelial ovarian cancer (EOC). Patients and Methods: ...
-
Article
Evaluation of six tumor markers in patients with carcinoma of unknown primary
Pavlidis, Nicholas; Kalef-Ezra, J. A.; Briassoulis, E. Ch; Skarlos, Dimosthenis V.; Kosmidis, Paraskevas A.; Saferiadis, K.; Bairaktari, Eleni Th; Bafaloukos, Dimitrios; Maravegias, A.; Theoharis, D.; Fountzilas, George (1994)We have retrospectively evaluated six serum tumor markers in 85 patients with carcinoma of unknown primary. The serum levels of carcinoembryonic antigen (CEA), CA 19‐9, CA 15‐3, CA 125, β‐chorionic gonadotropin (β‐HCG) and ...
-
Article
First-line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advanced breast cancer (final report): A phase II study conducted by the Hellenic Cooperative Oncology Group
Fountzilas, George; Dimopoulos, M. A.; Papadimitriou, C.; Kalogera-Fountzila, Anna; Aravantinos, Gerasimos; Bafaloukos, Dimitrios; Athanasiades, A.; Nikolaides, C.; Keramopoulos, A.; Pavlidis, Nicholas; Kosmidis, Paraskevas A.; Skarlos, Dimosthenis V. (1998)Purpose: To evaluate the activity and toxicity of the combination of paclitaxel given by three-hour infusion, and carboplatin as first- line chemotherapy in patients with advanced breast cancer (ABC). Background: Paclitaxel ...
-
Article
Fluorouracil and leucovorin with or without interferon alfa-2a as adjuvant treatment, in patients with high-risk colon cancer. A randomized phase III study conducted by the Hellenic Cooperative Oncology Group
Fountzilas, George; Zisiadis, A.; Dafni, U.; Konstantaras, C.; Hatzitheoharis, G.; Papavramidis, S.; Bousoulegas, A.; Basdanis, G.; Giannoulis, E.; Dokmetzioglou, J.; Katsohis, C.; Nenopoulou, E.; Karvounis, N.; Briassoulis, E. Ch; Aravantinos, Gerasimos; Kosmidis, Paraskevas A.; Skarlos, Dimosthenis V.; Pavlidis, Nicholas (2000)Background: It has been shown in randomized studies that adjuvant treatment with the combination of fluorouracil (FU) and levamisole reduced the risk of recurrence and deaths of patients with stage III colon cancer. ...
-
Article
Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: Analysis of a prospective randomized phase III trial
Kosmidis, Paraskevas A.; Tsavaris, N.; Skarlos, Dimosthenis V.; Theocharis, D.; Samantas, E.; Pavlidis, Nicholas; Briassoulis, E. Ch; Fountzilas, George (1996)Purpose: To investigate if double modulation of fluorouracil (5-FU) with leucovorin (folinic acid [FA]) and interferon alfa-2b (IFN 2b) improves responses and survival in comparison to single modulation of 5-FU with FA. ...
-
Article
Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study
Skarlos, Dimosthenis V.; Kalofonos, H. P.; Fountzilas, George; Dimopoulos, M. A.; Pavlidis, Nicholas; Razi, E. D.; Economopoulos, T.; Pectasides, Dimitrios; Gogas, H.; Kosmidis, Paraskevas A.; Bafaloukos, Dimitrios; Klouvas, G. D.; Kyratzis, G.; Aravantinos, Gerasimos (2005)Background: A phase II study was conducted to evaluate the efficacy and toxicity of the combination of gemcitabine (GEM) and pegylated liposomal doxorubicin (PLD) in patients with platinum- and/or taxane-resistant/refractory ...
-
Article
Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: A quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial
Pentheroudakis, George; Kalogeras, K. T.; Wirtz, R. M.; Grimani, I.; Zografos, G.; Gogas, H.; Stropp, U.; Pectasides, Dimitrios; Skarlos, Dimosthenis V.; Hennig, G.; Samantas, E.; Bafaloukos, Dimitrios; Papakostas, P.; Kalofonos, H. P.; Pavlidis, Nicholas; Fountzilas, George (2009)Background Estrogen receptor (ER) and progesterone receptor (PgR) protein expression carry weak prognostic and moderate predictive utility for the outcome of early breast cancer patients on adjuvant chemohormonotherapy. ...
-
Article
High-dose epirubicin as a single agent in the treatment of patients with advanced breast cancer. A Hellenic Co-operative Oncology Group study
Fountzilas, George; Skarlos, Dimosthenis V.; Pavlidis, Nicholas; Makrantonakis, P.; Tsavaris, N.; Kalogera-Fountzila, Anna; Giannakakis, T.; Beer, M.; Kosmidis, Paraskevas A. (1991)Fifty-two women with advanced breast cancer were treated with 6 cycles of epirubicin. Even though the study was started with a dose schedule of 110 mg/m2 every 3 weeks, the average treatment interval was 26 days and the ...
-
Article
High‐dose epirubicin and r‐met‐hu G‐CSF (Filgrastim) in the treatment of patients with advanced breast cancer: A hellenic cooperative oncology group study
Fountzilas, George; Skarlos, Dimosthenis V.; Katsohis, C.; Pavlidis, Nicholas; Giannakakis, T.; Bafaloukos, Dimitrios; Fahantidis, E.; Klouvas, G. D.; Beer, M.; Kosmidis, Paraskevas A. (1995)The delivery of high‐dose epirubicin in patients with advanced breast cancer usually entails serious myelotoxicity and frequent treatment delays. Concurrent administration of G‐CSF probably allows the administration of ...
-
Article
Ifosfamide plus oral etoposide salvage chemotherapy for platinum- resistant paclitaxel-pretreated ovarian cancer
Aravantinos, Gerasimos; Dimopoulos, M. A.; Kosmidis, Paraskevas A.; Bafaloukos, Dimitrios; Papadimitriou, C.; Kiamouris, Ch; Pavlidis, Nicholas; Sikiotis, K.; Papakostas, P.; Skarlos, Dimosthenis V. (2000)Background: The prognosis of platinum resistant ovarian cancer is very poor and the treatment of choice has not been clearly defined. Patients and methods: We conducted a phase II study with the combination of ifosfamide ...
-
Article
Intensified carboplatin regimen with GM-CSF support in non-small cell lung cancer (NSCLC). A Hellenic Co-operative Oncology Group study (HeCOG)
Nikolaides, C.; Klouvas, G. D.; Fountzilas, George; Athanasiades, A.; Skarlos, Dimosthenis V.; Samantas, E.; Kosmidis, Paraskevas A.; Mylonakis, N.; Pavlidis, Nicholas (1997)This is a continuation of a HeCOG previous trial utilizing carboplatin and vindesine in conventional doses as a non-toxic regimen provided easily on an outpatient basis in NSCLC. In the present study we investigated whether ...
-
Article
Intensive chemotherapy with high-dose epirubicin every 2 weeks and prophylactic administration of filgrastim in advanced breast cancer
Fountzilas, George; Skarlos, Dimosthenis V.; Giannakakis, T.; Athanasiades, A.; Bafaloukos, Dimitrios; Kalogera-Fountzila, Anna; Bamia, C.; Pavlidis, Nicholas; Kosmidis, Paraskevas A. (1994)50 women with advanced breast cancer were treated with an intensified regimen which consisted of high-dose epirubicin (110 mg/m2) every 2 weeks and filgrastim (5 μg/kg) subcutaneously for 13 days, starting 24 h after ...
-
Article
Megestrol acetate in cancer patients with anorexia and weight loss a hellenic co-operative oncology group (heCOG) study
Skarlos, Dimosthenis V.; Fountzilas, George; Pavlidis, Nicholas; Beer, M.; Makrantonakis, P.; Aravantinos, Gerasimos; Pantelakos, P.; Tsavaris, N.; Karpasitis, N.; Kosmidis, Paraskevas A. (1993)Fifty-two patients with hormone-independent cancer, who complained of anorexia and of weight loss with at least 10% received megestrol acetate (MA), 480 mg daily, during 1-21 weeks. of the 41 patients treated during 4 weeks ...
-
Article
Metastatic breast cancer with liver metastases: A registry analysis of clinicopathologic, management and outcome characteristics of 500 women
Pentheroudakis, George; Fountzilas, George; Bafaloukos, Dimitrios; Koutsoukou, V.; Pectasides, Dimitrios; Skarlos, Dimosthenis V.; Samantas, E.; Kalofonos, H. P.; Gogas, H.; Pavlidis, Nicholas (2006)Introduction. Breast cancer patients developing liver metastases have traditionally been considered to make up a poor prognosis group with median survival rates of less than 6 months. We retrospectively analysed clinicopathologic ...
-
Article
Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: A hellenic cooperative oncology group study
Briassoulis, E. Ch; Fountzilas, George; Bamias, A. T.; Dimopoulos, M. A.; Xiros, N.; Aravantinos, Gerasimos; Samantas, E.; Kalofonos, H. P.; Makatsoris, T.; Mylonakis, N.; Papakostas, P.; Skarlos, Dimosthenis V.; Varthalitis, I.; Pavlidis, Nicholas (2008)Background: Cancer of unknown primary (CUP) lacks established therapy although it affects 3% of cancer patients. We evaluated the irinotecan- oxaliplatin combination (IROX regimen) in previously untreated patients with ...
-
Article
Original article: Subsets of tumors responsive to cisplatin or carboplatin combinations in patients with carcinoma of unknown primary site: A hellenic cooperative oncology group study
Pavlidis, Nicholas; Kosmidis, Paraskevas A.; Skarlos, Dimosthenis V.; Briassoulis, E. Ch; Beer, M.; Theoharis, D.; Bafaloukos, Dimitrios; Maravegias, A.; Fountzilas, George (1992)Summary: In this retrospective analysis 48 patients with metastatic undifferentiated carcinoma, adenocarcinoma and epidermoid carcimona of unknown origin were studied. The purpose of this analysis was to evaluate both the ...
-
Article
Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): A multicenter randomized trial
Kosmidis, Paraskevas A.; Mylonakis, N.; Skarlos, Dimosthenis V.; Samantas, E.; Dimopoulos, M. A.; Papadimitriou, C.; Kalofonos, H. P.; Pavlidis, Nicholas; Nikolaides, C.; Papaconstantinou, C.; Fountzilas, George (2000)Purpose: The combination of paclitaxel and carboplatin has become a widely used regimen in NSCLC due to phase II reports of moderate toxicity, reasonable activity and easy outpatient administration. Purpose of our present ...
-
Article
Paclitaxel (175 mg/m2) plus carboplatin versus paclitaxel (225 mg/m2) plus carboplatin in non-small cell lung cancer: A randomized study
Kosmidis, Paraskevas A.; Mylonakis, N.; Fountzilas, George; Samantas, E.; Athanasiades, A.; Pavlidis, Nicholas; Skarlos, Dimosthenis V. (1997)A recent phase II study by our group documented a response rate of 27% with the combination paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 175 mg/m2 plus carboplatin dosed to a target area under the ...
-
Article
Paclitaxel (175 mg/m2) plus carboplatin versus paclitaxel (225 mg/m2) plus carboplatin in non-small cell lung cancer: a randomized study.
Kosmidis, Paraskevas A.; Mylonakis, N.; Fountzilas, George; Samantas, E.; Athanasiades, A.; Pavlidis, Nicholas; Skarlos, Dimosthenis V. (1997)A recent phase II study by our group documented a response rate of 27% with the combination paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 175 mg/m2 plus carboplatin dosed to a target area under the ...
-
Article
Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: A phase I/II study conducted by the Hellenic Cooperative Oncology Group
Fountzilas, George; Pectasides, Dimitrios; Kalogera-Fountzila, Anna; Skarlos, Dimosthenis V.; Kalofonos, H. P.; Papadimitriou, C.; Bafaloukos, Dimitrios; Lambropoulos, S.; Papadopoulos, S.; Kourea, H.; Markopoulos, C.; Linardou, H.; Mavroudis, D.; Briassoulis, E. Ch; Pavlidis, Nicholas; Razi, E. D.; Kosmidis, Paraskevas A.; Gogas, H. (2005)Paclitaxel (TaxolR) and carboplatin are an effective combination regimen for treating advanced breast cancer. Gefitinib (IRESSA) is the first epidermal growth factor receptor tyrosine kinase inhibitor to be approved for ...